The Texas high-speed rail just got a boost. Photo courtesy of JR Central

On November 5, the U.S. House of Representatives passed the Infrastructure Investment and Jobs Act, legislation that's anticipated to produce hundreds of thousands of union jobs and transform the U.S. transportation system, with investments in passenger rail, roads, and bridges.

A release from Environment Texas, a grass-roots environmental group, shares some of the many positive effects the package is anticipated to have on Texas' transportation and power infrastructure, and its stores of clean water.

Key environmental provisions include:

  • Lead pipes removal. There are an estimated 270,000 lead service lines still in Texas. Texas is expected to receive $2.9 billion over five years. The state had 6000 sewage overflows in 2019, leading the American Society of Civil Engineers to give Texas' wastewater infrastructure a grade of D.
  • Building electric vehicle charging stations. Texas needs an estimated 12,400 level-2 charging stations and 1,720 level-3 "fast charging stations" by 2030 to meet projected demand. The state will receive $408 million over five years and can apply for $2.5 billion in grant funding.
  • Improve electric grid and power infrastructure. This is obviously something Texas sorely needs, after the great freeze in February 2021 when transmission constraints contributed to blackouts across the state, leading to curtailments of wind and solar energy.
  • New passenger and freight rail. Amtrak has proposed new rail service connecting Houston to Dallas, Fort Worth, Austin, San Antonio, while Texas Central is working to build high speed rail between Houston and Dallas. According to Environment Texas, these projects could potentially benefit from the new funding.
  • New public transit. The bill dedicates $39 billion to new public transit projects, described as the largest investment in public transit in history. Texas stands to receive $3.3 billion over five years, with likely recipients to include Houston's MetroNext and Austin's Project Connect.
  • Environmental remediation. Texas has 55 superfund sites, 32 abandoned mines, and 783,000 unplugged oil and gas wells. Oy.
  • More zero- and low-emission buses. At least 13 school districts in Texas have expressed interest in purchasing electric buses. Nine transit agencies in Texas have already, or plan to, purchase electric buses.

The legislature is still working on the Build Back Better Act, a budget reconciliation bill with clean energy tax incentives and other investments that would help the U.S. stall climate change and clean up our environment.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.